CN109562108A - 用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺 - Google Patents

用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺 Download PDF

Info

Publication number
CN109562108A
CN109562108A CN201780048301.3A CN201780048301A CN109562108A CN 109562108 A CN109562108 A CN 109562108A CN 201780048301 A CN201780048301 A CN 201780048301A CN 109562108 A CN109562108 A CN 109562108A
Authority
CN
China
Prior art keywords
disease
subject
blood
mna
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780048301.3A
Other languages
English (en)
Chinese (zh)
Inventor
K·帕尔卡
J·格比基
M·维佐科夫斯卡
E·A·塞法利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Famina Biotechnology Co
Original Assignee
Famina Biotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Famina Biotechnology Co filed Critical Famina Biotechnology Co
Publication of CN109562108A publication Critical patent/CN109562108A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780048301.3A 2016-07-18 2017-07-16 用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺 Pending CN109562108A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363712P 2016-07-18 2016-07-18
US62/363,712 2016-07-18
PCT/IB2017/054293 WO2018015861A1 (en) 2016-07-18 2017-07-16 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein

Publications (1)

Publication Number Publication Date
CN109562108A true CN109562108A (zh) 2019-04-02

Family

ID=59399457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780048301.3A Pending CN109562108A (zh) 2016-07-18 2017-07-16 用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺

Country Status (12)

Country Link
US (1) US20190282560A1 (https=)
EP (1) EP3484475B1 (https=)
JP (1) JP2019521160A (https=)
CN (1) CN109562108A (https=)
AU (1) AU2017298648B2 (https=)
DK (1) DK3484475T3 (https=)
ES (1) ES2967074T3 (https=)
FI (1) FI3484475T3 (https=)
MX (1) MX389845B (https=)
PL (1) PL3484475T3 (https=)
RU (1) RU2744615C2 (https=)
WO (1) WO2018015861A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294786A (zh) * 2019-08-01 2021-02-02 深圳大学 一种含乙胺丁醇与他汀类药物的抗结核组合药物
CN116234542A (zh) * 2020-09-21 2023-06-06 加利福尼亚大学董事会 代谢物的免疫效应

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020115765A1 (en) 2018-12-05 2020-06-11 Celagenex Research (India) Pvt. Ltd. Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome
WO2021205341A1 (en) 2020-04-07 2021-10-14 Pharmena S.A. 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067927A2 (en) * 2004-01-12 2005-07-28 Pharmena Sp Z O.O. The use of quaternary pyridinium salts as vasoprotective agents
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2007074406A2 (en) * 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
WO2007103540A2 (en) * 2006-03-08 2007-09-13 Pharmena North America Inc. Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
WO2008104920A1 (en) * 2007-02-28 2008-09-04 Trigendo Sp. Z O.O. The use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
WO2009047291A2 (en) * 2007-10-12 2009-04-16 Politechnika Lódzka Use of quaternary pyridinium salts for inhibiting cancer metastases
CN102014916A (zh) * 2008-05-06 2011-04-13 科特里亚公司 1-甲基烟酰胺类似物
WO2014200373A1 (en) * 2013-06-11 2014-12-18 Uniwersytet Jagielloński 3-carbamoyl-1 -methylpyridinium nitrite, process for its preparation and its use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT131118B (de) 1929-04-19 1933-01-10 Ig Farbenindustrie Ag Verfahren zur Darstellung von N-Methylpyridiniumchlorid.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3614408A (en) 1969-02-20 1971-10-19 British Petroleum Co Waveform analyzing system, particularly for chromatographs, wherein the waveform is integrated between selected peaks and valleys
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4115390A (en) 1977-08-19 1978-09-19 Nardi John C Method for the preparation of 1-alkyl pyridinium chlorides
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US7030152B1 (en) 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
CA2629913A1 (en) * 2005-12-09 2007-06-14 Cerecon Ag Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
WO2009042440A1 (en) * 2007-09-28 2009-04-02 Cortria Corporation 1-methyl nicotinamide and derivatives for treatment of gastric injury
WO2011047358A1 (en) * 2009-10-15 2011-04-21 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067927A2 (en) * 2004-01-12 2005-07-28 Pharmena Sp Z O.O. The use of quaternary pyridinium salts as vasoprotective agents
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2007074406A2 (en) * 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
WO2007103540A2 (en) * 2006-03-08 2007-09-13 Pharmena North America Inc. Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
WO2008104920A1 (en) * 2007-02-28 2008-09-04 Trigendo Sp. Z O.O. The use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
WO2009047291A2 (en) * 2007-10-12 2009-04-16 Politechnika Lódzka Use of quaternary pyridinium salts for inhibiting cancer metastases
CN102014916A (zh) * 2008-05-06 2011-04-13 科特里亚公司 1-甲基烟酰胺类似物
WO2014200373A1 (en) * 2013-06-11 2014-12-18 Uniwersytet Jagielloński 3-carbamoyl-1 -methylpyridinium nitrite, process for its preparation and its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
谢复役等: "敏感特异的炎症标志物-C反应蛋白在临床中的应用进展", 《陕西医学检验》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294786A (zh) * 2019-08-01 2021-02-02 深圳大学 一种含乙胺丁醇与他汀类药物的抗结核组合药物
CN116234542A (zh) * 2020-09-21 2023-06-06 加利福尼亚大学董事会 代谢物的免疫效应

Also Published As

Publication number Publication date
PL3484475T3 (pl) 2024-03-11
FI3484475T3 (fi) 2023-12-12
MX389845B (es) 2025-03-20
ES2967074T3 (es) 2024-04-25
RU2019104343A3 (https=) 2020-09-17
MX2019000721A (es) 2019-06-10
US20190282560A1 (en) 2019-09-19
RU2019104343A (ru) 2020-08-18
AU2017298648B2 (en) 2023-05-11
JP2019521160A (ja) 2019-07-25
CA3030805A1 (en) 2018-01-25
DK3484475T3 (da) 2023-11-27
AU2017298648A1 (en) 2019-01-31
EP3484475B1 (en) 2023-09-27
WO2018015861A1 (en) 2018-01-25
EP3484475A1 (en) 2019-05-22
RU2744615C2 (ru) 2021-03-11

Similar Documents

Publication Publication Date Title
Soraci et al. Safety and tolerability of antimicrobial agents in the older patient
CN109562108A (zh) 用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺
Boldery et al. Nutritional deficiency of selenium secondary to weight loss (bariatric) surgery associated with life-threatening cardiomyopathy
US20230310455A1 (en) Combination therapies for treatment of her2 cancer
CN116173014A (zh) 用阿曲生坦治疗IgA肾病的方法
TW201609088A (zh) 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途
US20210353648A1 (en) Grapiprant unit dosage forms
JP2020519576A (ja) 肝細胞癌の治療
Zyad et al. GERD: Latest update on acid-suppressant drugs
EP4188384A1 (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
TWI863962B (zh) 癌症治療
Iacob et al. Long Term Follow-up of Liver Transplant Recipients: Considerations for Non-transplant Specialists.
Alnaqbi et al. Cardiac arrhythmia and heart failure shortly after starting romosozumab for osteoporosis: a case-based review
US20240390358A1 (en) Aggressive lipid lowering therapy in coronary artery disease
KR20170125927A (ko) 골밀도의 조절 방법
US20240293369A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CN101229372A (zh) 一种治疗高血压的药物组合物
WO2020136879A1 (ja) 悪性腫瘍を治療するための免疫療法剤の有用性の提示方法及び悪性腫瘍を治療するための免疫療法剤
CA3030805C (en) 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein
KR20230027226A (ko) 화학요법-유발 설사를 치료하기 위한 방법 및 조성물
US20250114363A1 (en) Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high serum uric acid level
JP2025517355A (ja) アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法
WO2026084690A1 (en) Fgfr3 inhibitor dosing regimens for use in treating cancer
JP2025512921A (ja) （１９ｒ）－５－クロロ－３－エチル－１６－フルオロ－１０，１９－ジメチル－２０－オキサ－３，４，１０，１１，２３－ペンタアザペンタシクロ［１９．３．１．０２，６．０８，１２．０１３，１８］ペンタコサ－１（２４），２（６），４，８，１１，１３，１５，１７，２１（２５），２２－デカエン－２２－アミンを使用して固形腫瘍の治療する方法
CN121263186A (zh) 用厄达替尼治疗局部晚期或转移性尿路上皮癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190402